Literature DB >> 1690512

Use of monoclonal antibodies to keratin 7 in the differential diagnosis of adenocarcinomas.

F Ramaekers1, C van Niekerk, L Poels, E Schaafsma, A Huijsmans, H Robben, G Schaart, P Vooijs.   

Abstract

Monoclonal antibodies (MAbs) to specific keratin subtypes were prepared and characterized by immunoblotting and immunohistochemical assays on human cell cultures and normal and malignant human tissues. Chain-specific MAbs to keratin 7 (RCK 105, OV-TL 12/30) and keratin 18 (RGE 53, RCK 106, CK18-2), as well as broadly cross-reacting keratin MAbs (RCK 102, OV-TL 12/5) could be shown to react with different types of human epithelial tissues and were therefore tested for their usefulness in the differential diagnosis of carcinomas. The two broad-spectrum antibodies stained virtually all of the more than 350 carcinomas tested, especially when combined, and distinguished them from most nonepithelial tumors. The keratin 18 MAbs distinguished adenocarcinomas (which are keratin 18 positive) from most squamous cell carcinomas (which are generally keratin 18 negative). The MAbs to keratin 7 could be shown to recognize specific subtypes of adenocarcinoma and could, for example, distinguish between ovarian carcinomas (keratin 7 positive) and carcinomas of the gastrointestinal tract (keratin 7 negative), or between transitional cell carcinomas (keratin 7 positive) and prostate cancer (keratin 7 negative). In general, malignancies showed the expected keratin reactivity pattern as concluded from the keratin pattern of its cell of origin or its type of differentiation. The use of an extended series of malignancies did, however, also illustrate that exceptions to this rule exist. For example, certain antibodies to keratin 18 stained tumor areas in squamous cell carcinomas of the lung. Also a certain percentage of tumors, which generally showed no keratin 7 expression, were positive with RCK 105 or OV-TL 12/30. On the other hand, a certain percentage of tumors, which were generally positive for keratin 7, did not show a staining reaction with these MAbs. Furthermore subtle differences between reactivity patterns of different MAbs recognizing the same keratin protein were observed, both in the normal and malignant human tissues, indicating that specific keratin epitopes may be masked in certain tissues and that unmasking of such epitopes can occur with malignant progression. This phenomenon may be of some use in a further subtyping of carcinomas, especially those of the gastrointestinal tract. Despite these exceptional staining patterns, the keratin MAbs described above have proved to be useful tools in the characterization of epithelial tumors in routine histopathology and cytopathology, in which they add to a more refined diagnosis of (adeno)carcinomas.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1690512      PMCID: PMC1877485     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  31 in total

1.  Continuous cultures of fused cells secreting antibody of predefined specificity.

Authors:  G Köhler; C Milstein
Journal:  Nature       Date:  1975-08-07       Impact factor: 49.962

2.  Cytokeratins in normal and malignant transitional epithelium. Maintenance of expression of urothelial differentiation features in transitional cell carcinomas and bladder carcinoma cell culture lines.

Authors:  R Moll; T Achtstätter; E Becht; J Balcarova-Ständer; M Ittensohn; W W Franke
Journal:  Am J Pathol       Date:  1988-07       Impact factor: 4.307

3.  Cytokeratins in smooth muscle cells and smooth muscle tumours.

Authors:  F C Ramaekers; M Pruszczynski; F Smedts
Journal:  Histopathology       Date:  1988-05       Impact factor: 5.087

4.  Distribution of cytokeratin polypeptides in epithelia of the adult human urinary tract.

Authors:  H E Schaafsma; F C Ramaekers; G N van Muijen; E C Ooms; D J Ruiter
Journal:  Histochemistry       Date:  1989

5.  Keratin immunohistochemistry in normal human liver. Cytokeratin pattern of hepatocytes, bile ducts and acinar gradient.

Authors:  P van Eyken; R Sciot; B van Damme; C de Wolf-Peeters; V J Desmet
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

6.  Absence of cytokeratin 8 and inconsistent expression of cytokeratins 7 and 19 in human basal cell carcinoma.

Authors:  J M Habets; B Tank; V D Vuzevski; J Brevé; E Stolz; T van Joost
Journal:  Anticancer Res       Date:  1988 Jul-Aug       Impact factor: 2.480

7.  Application of keratin immunocytochemistry and sirius red staining in evaluating intrahepatic changes with acute extrahepatic cholestasis due to hepatic duct carcinoma.

Authors:  J James; N J Lygidakis; P van Eyken; A K Tanka; K S Bosch; F C Ramaekers; V Desmer
Journal:  Hepatogastroenterology       Date:  1989-06

8.  Characterization of a human ovarian carcinoma cell line, OTN 14, derived from a mucinous cystadenocarcinoma.

Authors:  C C van Niekerk; L G Poels; P H Jap; D F Smeets; C M Thomas; F C Ramaekers; G P Vooijs
Journal:  Int J Cancer       Date:  1988-07-15       Impact factor: 7.396

9.  Patterns of expression of trichocytic and epithelial cytokeratins in mammalian tissues. I. Human and bovine hair follicles.

Authors:  H W Heid; I Moll; W W Franke
Journal:  Differentiation       Date:  1988       Impact factor: 3.880

10.  Monoclonal antibody mapping of keratins 8 and 17 and of vimentin in normal human mammary gland, benign tumors, dysplasias and breast cancer.

Authors:  V I Guelstein; T A Tchypysheva; V D Ermilova; L V Litvinova; S M Troyanovsky; G A Bannikov
Journal:  Int J Cancer       Date:  1988-08-15       Impact factor: 7.396

View more
  44 in total

1.  Cytokeratin expression in the epithelia of the adult human cochlea.

Authors:  L J Bauwens; J C DeGroot; F C Ramaekers; J E Veldman; E H Huizing
Journal:  Eur Arch Otorhinolaryngol       Date:  1991       Impact factor: 2.503

2.  Cytokeratin intermediate filament expression in benign and malignant breast disease.

Authors:  M Heatley; P Maxwell; C Whiteside; P Toner
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

3.  Detection of keratin subtypes in routinely processed cervical tissue: implications for tumour classification and the study of cervix cancer aetiology.

Authors:  F Smedts; F Ramaekers; M Link; L Lauerova; S Troyanovsky; C Schijf; G P Vooijs
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

4.  Cytokeratin expression patterns in metastatic transitional cell carcinoma of the urinary tract. An immunohistochemical study comparing local tumor and autologous metastases.

Authors:  H E Schaafsma; F C Ramaekers; G N van Muijen; H Robben; E B Lane; I M Leigh; E C Ooms; J A Schalken; R J van Moorselaar; D J Ruiter
Journal:  Am J Pathol       Date:  1991-12       Impact factor: 4.307

5.  The limited difference between keratin patterns of squamous cell carcinomas and adenocarcinomas is explicable by both cell lineage and state of differentiation of tumour cells.

Authors:  E B van Dorst; G N van Muijen; S V Litvinov; G J Fleuren
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

Review 6.  Metachronous metastasis from the right colon adenocarcinoma to the vulva: an unusual report and literature review.

Authors:  Kexing Ren; Xuelei Ma; Feng Wang; Fuchun Guo; Yu Jiang; Lei Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

7.  Expression of cytokeratins 7 and 20 in serrated adenoma and related diseases.

Authors:  Natsuko Tatsumi; Ken-Ichi Mukaisho; Shoji Mitsufuji; Yoichi Tatsumi; Hiroyuki Sugihara; Takeshi Okanoue; Takanori Hattori
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

8.  Multiple primary cancers of the colon, rectum, and the thyroid gland.

Authors:  Ahmad Zubaidi
Journal:  Saudi J Gastroenterol       Date:  2008-10       Impact factor: 2.485

9.  Translational regulation of human papillomavirus type 16 E7 mRNA by the peptide SEQIKA, shared by rabbit alpha(1)-globin and human cytokeratin 7.

Authors:  Darja Kanduc
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  Keratin expression in cervical cancer.

Authors:  F Smedts; F Ramaekers; S Troyanovsky; M Pruszczynski; M Link; B Lane; I Leigh; C Schijf; P Vooijs
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.